Alnylam says drug for Huntington's shows promise | STAT (opens in a new tab)

statnews.com · 2026-10-23

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

17 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail

The story

Alnylam says drug for Huntington's shows promise | STAT

statnews.com · 2026-10-23

The story’s checkable claims.

Read the original story

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Reading mode

Scan verdicts. Open evidence only when needed.

Claim 1 of 3Not checkedAlnylam Pharmaceuticals said its experimental Huntington’s drug, brezosiran, showed promise in a small study.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 3Not checkedPatients who received the highest dose of brezosiran saw mutant huntingtin levels in their spinal fluid fall by 60% or 64% on average, depending on the assay used.View evidenceHide evidence

As stated60% or 64% on average

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 3Not checkedThe company described the drug’s safety profile as encouraging and said it planned to start a placebo-controlled study next year to test whether the drug can actually slow the disease.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results